Media headlines about Atara Biotherapeutics (NASDAQ:ATRA) have trended somewhat positive on Monday, according to Accern Sentiment Analysis. The research firm rates the sentiment of news coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Atara Biotherapeutics earned a media sentiment score of 0.17 on Accern’s scale. Accern also gave news stories about the biotechnology company an impact score of 46.3167472160679 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
These are some of the media headlines that may have impacted Accern Sentiment Analysis’s rankings:
- Atara Biotherapeutics, Inc. (ATRA) CEO Isaac E. Ciechanover Sells 4,400 Shares (americanbankingnews.com)
- ATARA Biotherapeutics (ATRA) Receives Rare Pediatric Disease Designation from FDA for ATA230 for Treatment of CMV (streetinsider.com)
- Atara Biotherapeutics Receives Rare Pediatric Disease Designation from FDA for ATA230 for Treatment of Congenital Cytomegalovirus (CMV) Infection (finance.yahoo.com)
- Atara Biotherapeutics Inc (ATRA) to Release Earnings on Thursday (americanbankingnews.com)
- Atara Biotherapeutics Announces Six of Ten Progressive Multiple Sclerosis (MS) Patients Experienced Clinical Improvements in an Ongoing Phase 1 Study of Autologous ATA190 (finance.yahoo.com)
Atara Biotherapeutics (NASDAQ ATRA) traded up 4.04% during trading on Monday, hitting $14.15. 188,985 shares of the company traded hands. Atara Biotherapeutics has a 12-month low of $11.80 and a 12-month high of $23.00. The stock has a 50 day moving average price of $15.37 and a 200 day moving average price of $15.02. The company’s market capitalization is $432.41 million.
Atara Biotherapeutics (NASDAQ:ATRA) last released its quarterly earnings data on Monday, August 7th. The biotechnology company reported ($0.94) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.89) by ($0.05). On average, equities analysts anticipate that Atara Biotherapeutics will post ($3.90) earnings per share for the current year.
Several equities analysts have commented on the stock. ValuEngine upgraded shares of Atara Biotherapeutics from a “strong sell” rating to a “sell” rating in a report on Friday, September 1st. BidaskClub downgraded shares of Atara Biotherapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, August 22nd. Canaccord Genuity set a $47.00 price objective on shares of Atara Biotherapeutics and gave the company a “buy” rating in a report on Monday, August 7th. Zacks Investment Research downgraded shares of Atara Biotherapeutics from a “buy” rating to a “hold” rating in a report on Monday, August 28th. Finally, Jefferies Group LLC reiterated a “buy” rating and issued a $30.00 price objective on shares of Atara Biotherapeutics in a report on Thursday, October 5th. Three analysts have rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the stock. Atara Biotherapeutics presently has a consensus rating of “Hold” and an average target price of $24.40.
TRADEMARK VIOLATION NOTICE: This report was reported by Community Financial News and is owned by of Community Financial News. If you are viewing this report on another site, it was copied illegally and republished in violation of United States and international copyright legislation. The legal version of this report can be viewed at https://www.com-unik.info/2017/10/30/atara-biotherapeutics-atra-receiving-somewhat-positive-press-coverage-study-finds.html.
In other Atara Biotherapeutics news, EVP Christopher Haqq sold 7,604 shares of the company’s stock in a transaction dated Tuesday, August 15th. The shares were sold at an average price of $14.75, for a total transaction of $112,159.00. Following the sale, the executive vice president now directly owns 362,909 shares of the company’s stock, valued at $5,352,907.75. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Isaac E. Ciechanover sold 4,400 shares of the company’s stock in a transaction dated Wednesday, August 23rd. The shares were sold at an average price of $13.54, for a total transaction of $59,576.00. Following the sale, the chief executive officer now directly owns 737,767 shares in the company, valued at $9,989,365.18. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 56,609 shares of company stock worth $828,405. Insiders own 16.20% of the company’s stock.
About Atara Biotherapeutics
Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells.
What are top analysts saying about Atara Biotherapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Atara Biotherapeutics Inc. and related companies.